Swiss National Bank Boosts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Swiss National Bank raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 15.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 76,200 shares of the company's stock after acquiring an additional 10,300 shares during the quarter. Swiss National Bank owned approximately 0.12% of Kymera Therapeutics worth $3,066,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in KYMR. Wellington Management Group LLP grew its holdings in Kymera Therapeutics by 7.2% in the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company's stock worth $218,587,000 after purchasing an additional 308,954 shares during the last quarter. FMR LLC lifted its holdings in shares of Kymera Therapeutics by 5.8% during the third quarter. FMR LLC now owns 5,109,141 shares of the company's stock worth $241,816,000 after purchasing an additional 282,301 shares during the period. JPMorgan Chase & Co. raised its position in Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after buying an additional 95,547 shares during the last quarter. Cinctive Capital Management LP acquired a new stake in Kymera Therapeutics during the 3rd quarter valued at approximately $2,688,000. Finally, Eventide Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company's stock valued at $24,039,000 after acquiring an additional 45,803 shares during the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on KYMR shares. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Leerink Partners reissued an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Wells Fargo & Company raised Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. Stephens reissued an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, BTIG Research started coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a "buy" rating and a $60.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $56.36.

Insider Transactions at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the transaction, the insider now owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,788 shares of company stock worth $455,202 in the last ninety days. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Stock Down 1.9 %

Shares of NASDAQ KYMR traded down $0.58 during trading on Friday, hitting $29.62. The company had a trading volume of 357,093 shares, compared to its average volume of 522,181. Kymera Therapeutics, Inc. has a fifty-two week low of $29.07 and a fifty-two week high of $53.27. The stock has a fifty day simple moving average of $35.86 and a two-hundred day simple moving average of $41.75. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -12.66 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.